Laddar...
EMT is associated with, but does not drive resistance to ALK inhibitors among EML4‐ALK non‐small cell lung cancer
ALK gene fusion occurs in approximately 3–7% of non‐small cell lung cancer (NSCLC). For patients with ALK positive NCSLC, crizotinib and ceritinib are FDA approved ALK inhibitors, however, patients inevitably acquire resistance to such therapies typically within one to two years. Interrogation of in...
Sparad:
| I publikationen: | Mol Oncol |
|---|---|
| Huvudupphovsmän: | , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
John Wiley and Sons Inc.
2015
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5423150/ https://ncbi.nlm.nih.gov/pubmed/26639656 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2015.11.007 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|